Status: current, Not sufficiently defined by necessary conditions definition status. Date: 31-Jan 2021. Module: SNOMED CT core module
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3993967018 | Tazemetostat hydrobromide | en | Synonym | Active | Entire term case insensitive | SNOMED CT core module |
| 3993968011 | Tazemetostat hydrobromide (substance) | en | Fully specified name | Active | Entire term case insensitive | SNOMED CT core module |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Tazemetostat hydrobromide | Is a | Substance with enzyme inhibitor mechanism of action | false | Inferred relationship | Existential restriction modifier | ||
| Tazemetostat hydrobromide | Is a | Substance with methyltransferase inhibitor mechanism of action | true | Inferred relationship | Existential restriction modifier | ||
| Tazemetostat hydrobromide | Is modification of | Tazemetostat | true | Inferred relationship | Existential restriction modifier | ||
| Tazemetostat hydrobromide | Has disposition | Methyltransferase inhibitor | true | Inferred relationship | Existential restriction modifier | ||
| Tazemetostat hydrobromide | Is a | Antineoplastic agent | true | Inferred relationship | Existential restriction modifier | ||
| Tazemetostat hydrobromide | Is a | Substance with benzamide structure | true | Inferred relationship | Existential restriction modifier |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
| Product containing precisely tazemetostat (as tazemetostat hydrobromide) 200 milligram/1 each conventional release oral tablet (clinical drug) | Has precise active ingredient | True | Tazemetostat hydrobromide | Inferred relationship | Existential restriction modifier | 1 |
This concept is not in any reference sets
FHIR